Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2007

View Archived Issues

Six-month study shows prevention of depressive relapses with agomelatine

Recent Atir patent discloses novel agents for male sexual dysfunction

Novel antiinfectious agent reported in recent patent literature

Recent patents report novel therapeutic agents for neurological disorders

AST-120 effective in pouchitis pilot study

MBP-8298 safe in phase III MAESTRO-01 multiple sclerosis trial

Minocycline beneficial in patients with acute stroke

Aida identifies potential targets in phase II trial with Rh-Apo2L

Dynavax starts environmental exposure chamber study of Tolamba

DepoDur modified-release injection approved in Australia

Aripiprazole ineffective in treating methamphetamine dependence

Avant and Celldex sign merger and provide update on future activity

Raptor establishes subsidiary and acquires first clinical-stage product

Kyowa Hakko and Kirin Pharma to merge

Can-Fite's CF-102 promotes liver tissue regeneration following partial hepatectomy

FDA and EMEA grant orphan drug status to SQ-109 for tuberculosis

Summit initiates phase I clinical trial of SMT-D002 for seborrhea in PD

Mutations in PEX2 identified as the cause of Zellweger syndrome

Dendreon completes enrollment in phase III trial of Provenge for advanced prostate cancer

Lu-AA-24530 enters phase II for mood and anxiety disorders

Oncolytics Biotech receives U.K. approval to evaluate Reolysin

Morria Biopharmaceuticals advances MRX-4 to phase I for allergic rhinitis

PAION commences phase I trial of Solulin

APITD1, a candidate tumor suppressor gene in neuroblastoma

Inhibitex begins phase I study of FV-100 for shingles

FDA accepts Wyeth's sNDA for Tygacil in CAP

FDA grants fast track designation to Phamasset's R-7128 in chronic HCV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...